TNFRSF4 and neoplasm: Importantly, all mice cured of tumors by optimal timing of anti-OX40 were resistant to rechallenge with CT26 tumors, but remained susceptible to a syngeneic antigenically distinct tumor, indicating long term antigen-specific immunity was achieved (Table 1).